**AGENDA**

**Translational Advances in Cancer Prevention Agent Development**

***Sponsored by the Division of Cancer Prevention, National Cancer Institute***

***and the Office of Disease Prevention***

***National Institutes of Health***

***Bethesda, MD 20892***

**DATE: August 27-29, 2020**

***Day 1 Morning Session (8:00 to 12:00)***

7:00-8:00 AM **Registration** (Please allow sufficient time to go through security)

8:00-8:30 AM **Welcome Remarks**

Deborah Winn, Ph.D., Acting Director, Division of Cancer Prevention, NCI

Mark Miller, Ph.D. Program Director, Division of Cancer Prevention, NCI

8:30-9:30 AM **Translational Research Plenary Speaker**

Raymond DuBois, M.D., Ph.D., Medical University of South Carolina

*Inflammation and inflammatory mediators as targets for cancer prevention/interception*

**Session I\***

**Advances in Small Molecule Agent Development**

*Co-Chairs: Margie Clapper, Ph.D. and Thomas Kensler, Ph.D.*

9:30-10:00 AM Speaker 1: Margie Clapper, Ph.D. Fox Chase Cancer Center

*Estrogen metabolism: A target for intervention in non-small cell lung cancer*

10:00-10:30 AM Speaker 2: Thomas Kensler, Ph.D., Fred Hutchinson Cancer Research Center

*Bringing broccoli sprouts (Sulforaphane) to clinical trials: dose matters*

**10:30-10:50 AM Break**

10:50-11:20 AM Speaker 3: Zelton (Dave) Sharp, Ph.D., University of Texas at San Antonio

*Cancer and aging prevention by mTOR inhibition*

11:20-11:50 AM Speaker 4: Karen Liby, Ph.D., Michigan State University

*Targeting the immune system for the prevention of Kras-driven cancers*

**11:50-1:15 PM**  **Lunch**

***Day 1 Afternoon Session (1:15 to 4:30)***

**Session II**

**Advances in Immunomodulatory Agent Development**

*Co-chairs: Jill Siegfried, Ph.D. and Robert H. Shoemaker, Ph.D.*

1:15-1:45 PM Speaker 1: Jill Siegfried, Ph.D., University of Minnesota

*A STAT3 decoy for lung cancer prevention*

1:45-2:15 PM Speaker 2: Robert Glynn, Sc.D., Harvard Medical School

*Mediation analysis to elucidate the role of inflammation reduction in cancer prevention: exploratory findings from the CANTOS trial*

2:15-2:45 PM Speaker 3: Haval Shirwan, Ph.D., University of Missouri, Columbia

*CD137 immune checkpoint pathway as an effective target for cancer immunoprevention*

2:45-3:00 PM Break

3:00-3:30 PM Speaker 4: Shadmehr Demehri, M.D., Ph.D., Massachusetts General Hospital

*Epithelium-derived alarmins role in breast cancer immunoprevention*

3:30-3:50 PM **NCI PREVENT Preclinical Drug Development Program**

Mark Miller, Ph.D., Division of Cancer Prevention, NCI

Q&A Session until 4:30 PM

**4:30-6:00 PM Poster Session**

***Day 2 Morning Session (9:00 to12:00)***

**Session III**

**Alternative Dosing and Combination Strategies to Reduce Toxicity**

*Co-Chairs: Ming You, M.D., Ph.D. and Altaf Mohammed, Ph.D.*

9:00-9:30 AM Speaker 1: Ming You, M.D., Ph.D., Wisconsin Medical Center

*Chemoprevention with aerosolized let-7 micro-RNA in mouse models of lung cancer*

9:30-10:00 AM Speaker 2: Susan Mallery, D.D.S., Ph.D., Ohio State University

*Location, location, location: oral cancer chemoprevention by local delivery*

10:00-10:30 AM Speaker 3: C.V. Rao, Ph.D., University of Oklahoma

*Safer chemopreventive approaches to colonic adenoma prevention*

**10:30-10:45 AM Break**

10:45-11:15 AM Speaker 4: D. Lynn Kirkpatrick, Ph.D., PHusis Therapeutics

*Preventing Skin cancer in high risk individuals with Actinic Keratosis using targeted AKT/PDK1 inhibitor, PHT-427*

11:15-11:45 AM Speaker 5: Roderick Dashwood, Ph.D., Texas A&M Health Science Center

*Optimizing dosing regimens of Erlotinib and Sulindac in a preclinical model of FAP*

**11:45-1:00 PM Lunch**

***Day 2 Afternoon Session (1:00 to 4:00)***

**Session IV**

**Emerging Vaccines for Cancer Prevention**

*Co-Chairs: Steven Lipkin, M.D., Ph.D. and Shizuko Sei, M.D.*

1:00-1:30 PM Speaker 1: Steven Lipkin, M.D., Ph.D. Weill Cornell University

*Immunoprevention for Lynch Syndrome*

1:30-2:00 PM Speaker 2: Mary (Nora) Disis, M.D., University of Washington

*Vaccines targeting cancer initiation associated proteins*

2:00-2:30 PM Speaker 3: Richard Roden, Ph.D., Johns Hopkins University

*Development of vaccines for broad protection against and elimination of HPV infection*

2:30-2:50 PM **Break**

2:50-3:20 PM Speaker 4: Robert Schoen, M.D., M.P.H., University of Pittsburgh

*MUC1 vaccine for prevention of colorectal adenoma*

3:20-3:50 PM Speaker 5: Bryon Johnson, Ph.D., Wisconsin Medical Center

*Development of a Kras preventive vaccine*

**4:00-6:00 PM Poster Session**

***Day 3 Morning Session (8:00 to 12:00)***

8:00-9:00 AM **Clinical Research Plenary Speaker**

Powel Brown, M.D., Ph.D., MD Anderson Cancer Center

*Novel cancer prevention strategies in the molecular era*

**Session V**

**Cancer Prevention Clinical Trials**

*Co-Chairs: Peter Allen and Eva Szabo*

9:00-9:15 AM **Overview of the Cancer Prevention Clinical Trials Network (CP-CTNet)**

Eva Szabo, M.D., Division of Cancer Prevention, NCI

Q&A to 9:30 AM

9:30-10:00 AM Speaker 1: Peter Allen, M.D., Duke University

*Intraductal Papillary Mucinous neoplasms of the pancreas:  An opportunity to prevent pancreatic cancer?*

10:00-10:30 AM Speaker 2, Eduardo Vilar-Sanchez, M.D., Ph.D., MD Anderson Cancer Center

*Cancer immune-interception for Lynch Syndrome*

**10:30-10:50 AM Break**

10:50-11:20 AM Speaker 3: Seema Khan, M.D., Northwestern University

*Local transdermal drug delivery to the breast for cancer prevention*

11:20-11:50 AM Speaker 4: Andrew Chan, M.D., M.P.H., Massachusetts General Hospital

*Novel strategies for aspirin prevention of cancer*

12:00 PM **Adjourn**